Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) has received an average rating of “Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $66.67.
SLNO has been the subject of a number of research reports. Robert W. Baird assumed coverage on shares of Soleno Therapeutics in a research note on Friday, May 10th. They set an “outperform” rating and a $72.00 target price for the company. Baird R W raised Soleno Therapeutics to a “strong-buy” rating in a report on Friday, May 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 target price on shares of Soleno Therapeutics in a report on Wednesday, July 31st. Finally, Oppenheimer boosted their price target on Soleno Therapeutics from $59.00 to $65.00 and gave the company an “outperform” rating in a research note on Monday, August 12th.
Get Our Latest Analysis on SLNO
Soleno Therapeutics Stock Down 6.9 %
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.06. As a group, sell-side analysts anticipate that Soleno Therapeutics will post -2.36 earnings per share for the current year.
Insider Activity at Soleno Therapeutics
In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 19,256 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $41.54, for a total transaction of $799,894.24. Following the sale, the chief executive officer now owns 133,534 shares in the company, valued at approximately $5,547,002.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Soleno Therapeutics news, insider Kristen Yen sold 2,170 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $41.54, for a total transaction of $90,141.80. Following the completion of the sale, the insider now directly owns 21,252 shares of the company’s stock, valued at approximately $882,808.08. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bhatnagar Anish sold 19,256 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $41.54, for a total transaction of $799,894.24. Following the transaction, the chief executive officer now directly owns 133,534 shares of the company’s stock, valued at $5,547,002.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,695 shares of company stock worth $4,396,224. 12.30% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC increased its holdings in shares of Soleno Therapeutics by 27.9% in the second quarter. Nantahala Capital Management LLC now owns 3,082,107 shares of the company’s stock worth $125,750,000 after purchasing an additional 671,728 shares during the last quarter. Perceptive Advisors LLC boosted its stake in Soleno Therapeutics by 4.2% during the second quarter. Perceptive Advisors LLC now owns 3,204,976 shares of the company’s stock valued at $130,763,000 after buying an additional 130,434 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in Soleno Therapeutics during the 2nd quarter valued at approximately $5,920,000. The Manufacturers Life Insurance Company increased its stake in Soleno Therapeutics by 120.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,408 shares of the company’s stock worth $2,016,000 after acquiring an additional 27,020 shares during the last quarter. Finally, Samlyn Capital LLC raised its holdings in shares of Soleno Therapeutics by 128.9% during the 2nd quarter. Samlyn Capital LLC now owns 501,049 shares of the company’s stock worth $20,443,000 after acquiring an additional 282,122 shares in the last quarter. Institutional investors own 97.42% of the company’s stock.
About Soleno Therapeutics
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
Featured Stories
- Five stocks we like better than Soleno Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 8/19 – 8/23
- Upcoming IPO Stock Lockup Period, Explained
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.